CorTec's Brain Interchange System Gains FDA Breakthrough Device Designation

CorTec GmbH, based in Freiburg, Germany, has announced receiving the FDA Breakthrough Device Designation for its Brain Interchange System. This system, focused on stroke rehabilitation, is the first of its kind globally designed for motor recovery in stroke patients. The designation is a step forward for medical technologies addressing critical or debilitating conditions, facilitating their development and review process with the FDA.

The Brain Interchange System integrates neural signal recording with adaptive stimulation in a closed-loop framework. Currently under evaluation in an FDA-approved study at the University of Washington, it represents the first clinical test of a fully implantable, wireless BCI for stroke rehabilitation in humans. Stroke remains a leading cause of long-term disability, affecting millions globally, making this advancement particularly significant.

CorTec's approach sets it apart within the brain-computer interface sector, with few companies reaching this regulatory milestone. It combines a fully implantable, bidirectional device allowing for both communication and therapeutic neurostimulation. The designation offers CorTec a pathway toward accelerated clinical trials and further regulatory milestones.